We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Agilent Obtains IVD Patent Licenses From Abbott

By HospiMedica staff writers
Posted on 08 Sep 2006
Agilent Technologies Inc. More...
(Palo Alto, CA, USA), has obtained worldwide, non-exclusive patent licenses from Abbott Molecular Inc.(Des Plaines, IL, USA), that cover microarray applications, including in vitro diagnostics (IVD), commercial laboratories, and research.

More specifically, the applications will be for the manufacture, marketing, and sale of oligonucleotide microarrays using a two-or-more color technology for gene expression and comparative genomic hybridization (CGH) applications. Expressly built into the grant of rights are related products, instruments, components and services. Other details of the licensing agreement were not disclosed.

"This intellectual property complements other recent Agilent investments in microarray fabrication technology and software,” said Nick Roelofs, vice president and general manager of Agilent's Life Sciences Solutions Unit.

Oligonucleotide microarrays comprise short sequences of nucleotides, often used as probes for detecting complementary DNA or RNA. Array CGH technology provides a way of studying chromosomal aberrations, including copy number changes and rearrangements, across the entire genome simultaneously. Ultimately, this information can be used to determine gene activity or to pinpoint chromosomal abnormalities such as gains or losses associated with disease states.

Agilent Technologies is a leading worldwide provider of microarray-based genomics research solutions. The company's product portfolio includes reagents for sample preparation and microarray processing, systems for sample quality control (QC) and high-throughput microarray scanning, 60-mer oligo microarrays and custom microarray design services, and industry-leading informatics tools, including GeneSpring and Rosetta Resolver.

Abbott Molecular provides doctors with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for an early diagnosis, selection of therapy, and monitoring of disease progression.



Related Links:
Agilent Technologies
Abbott Molecular

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Medical Monitor
SILENIO D
Blood Bank Refrigerator
MBR-705GR-PE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.